Global Recurrent Parotitis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Recurrent Parotitis Treatment Market Size

• The global recurrent parotitis treatment market size was valued at USD 5.83 billion in 2024 and is expected to reach USD 9.43 billion by 2032, at a CAGR of 6.20% during the forecast period
• The market growth is largely fueled by the increasing prevalence of recurrent parotitis cases, coupled with rising awareness among healthcare professionals regarding advanced treatment protocols
• Furthermore, advancements in minimally invasive surgical techniques and targeted therapies are enabling more effective management of recurrent parotitis, enhancing patient outcomes and driving market expansion

Recurrent Parotitis Treatment Market Analysis

• Recurrent Parotitis Treatment, encompassing medical and surgical interventions, is increasingly recognized as a critical aspect of managing chronic and recurring salivary gland disorders in both pediatric and adult populations due to its ability to reduce episodes of inflammation, prevent complications, and improve patient quality of life
• The escalating demand for recurrent parotitis treatment is primarily fueled by rising awareness of salivary gland disorders among patients and healthcare providers, increasing prevalence of chronic parotitis cases, and growing adoption of minimally invasive surgical techniques and targeted medical therapies that offer effective symptom management with reduced recovery times
• North America dominated the recurrent parotitis treatment market with the largest revenue share of 40% in 2024, driven by advanced healthcare infrastructure, growing awareness of salivary gland disorders, and the presence of leading healthcare providers and treatment centers. The U.S. leads the regional market due to the widespread availability of specialized otolaryngology clinics, advanced diagnostic facilities, and adoption of minimally invasive and innovative treatment options for recurrent parotitis
• Asia-Pacific is expected to be the fastest-growing region in the recurrent parotitis treatment market during the forecast period, fueled by increasing healthcare investments, rising prevalence of salivary gland disorders, expanding number of specialized treatment centers, and growing awareness about early diagnosis and minimally invasive therapies in countries such as China, India, and Japan
• The tablets segment dominated the recurrent parotitis treatment market with the largest market revenue share of 46.1% in 2024, owing to ease of use, patient compliance, and suitability for long-term prophylactic therapy

Report Scope and Recurrent Parotitis Treatment Market Segmentation      

Recurrent Parotitis Treatment Market Trends

Advancements in Minimally Invasive and Targeted Therapies

• A significant and accelerating trend in the global recurrent parotitis treatment market is the increasing adoption of minimally invasive procedures and targeted medical therapies. These approaches are improving treatment outcomes, reducing recurrence rates, and minimizing patient discomfort compared to conventional surgical methods
  • For instance, sialendoscopy, a minimally invasive technique, allows for precise removal of ductal obstructions and irrigation of the salivary glands, significantly reducing the frequency and severity of recurrent episodes. Similarly, targeted anti-inflammatory and antibiotic regimens are being optimized for individualized patient care, enhancing recovery and long-term management
• Advancements in imaging technologies, such as high-resolution ultrasonography and MRI, are enabling better diagnosis and monitoring of parotid gland pathology, allowing physicians to tailor treatment plans more effectively and reduce unnecessary interventions
• The integration of multidisciplinary approaches involving otolaryngologists, radiologists, and pediatric specialists is fostering more comprehensive care for patients, addressing both the acute episodes and underlying causes of recurrent parotitis
• This trend toward precision and patient-centric treatment is reshaping clinical practice standards globally, with hospitals and specialty clinics increasingly adopting evidence-based protocols to enhance outcomes
• Companies and research institutions are focusing on developing novel pharmacological agents, improved surgical tools, and innovative delivery methods to further reduce recurrence and improve quality of life for patients
• The demand for advanced recurrent parotitis treatment options is growing across both pediatric and adult populations, driven by increasing awareness among healthcare providers and patients regarding effective management strategies and long-term prevention of complications

Recurrent Parotitis Treatment Market Dynamics

Driver

Growing Need Due to Rising Prevalence and Awareness

• The increasing prevalence of recurrent parotitis, particularly among pediatric populations, coupled with rising awareness among healthcare providers and patients, is a significant driver for the heightened demand for advanced Recurrent Parotitis Treatment solutions
  • For instance, in March 2023, leading medical centers in the U.S. reported the adoption of sialendoscopy-based therapies as a minimally invasive intervention for recurrent parotitis, reflecting the market’s shift toward precision and patient-centric approaches. Such advancements are expected to drive the Recurrent Parotitis Treatment industry growth in the forecast period
• As healthcare providers seek more effective management strategies, treatment options that reduce recurrence frequency, improve gland function, and minimize patient discomfort are gaining prominence. Personalized treatment plans combining pharmacological, minimally invasive, and supportive care approaches are increasingly preferred over conventional surgical interventions
• Furthermore, growing research initiatives and clinical trials are enhancing the understanding of etiologies and optimal treatment protocols for recurrent parotitis, supporting the development of evidence-based practices in both pediatric and adult populations
• The increasing availability of advanced diagnostic imaging, including high-resolution ultrasonography and MRI, allows for accurate diagnosis, monitoring, and treatment planning, which is propelling the adoption of innovative therapies

Restraint/Challenge

Limited Awareness, High Costs, and Access to Advanced Therapies

• A major challenge to market growth is the limited awareness of advanced treatment options among certain healthcare providers and patients, particularly in developing regions. This can lead to reliance on traditional approaches with higher recurrence rates
• The relatively high cost of advanced Recurrent Parotitis Treatment procedures, such as sialendoscopy and targeted pharmacotherapy, can be a barrier to adoption for price-sensitive healthcare facilities and patients without adequate insurance coverage
• Availability of specialized treatment centers and trained specialists is limited in some regions, restricting patient access to minimally invasive and optimized therapeutic interventions
• While new therapies and interventions are being developed, delays in regulatory approvals and clinical adoption can slow market penetration and limit immediate availability
• Overcoming these challenges through increased awareness campaigns, training programs for medical professionals, expansion of specialized treatment centers, and efforts to reduce procedural costs will be vital for sustained market growth in the Recurrent Parotitis Treatment sector

Recurrent Parotitis Treatment Market Scope

The market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel.

• By Treatment

On the basis of treatment, the recurrent parotitis treatment market is segmented into medications, sialoendoscopy, parotidectomy, radiotherapy, tympanic neurectomy, and others. The medications segment dominated the largest market revenue share of 45.3% in 2024, driven by their non-invasive nature, ease of administration, and widespread availability. Medications, including antibiotics, anti-inflammatory drugs, and analgesics, are typically the first line of therapy to manage acute episodes and prevent complications. The preference for medications is also supported by healthcare practitioners’ focus on reducing patient discomfort and minimizing hospital visits. Their relatively lower cost compared to surgical interventions makes them accessible across both developed and emerging markets. In addition, the development of targeted pharmacological therapies has enhanced efficacy and patient compliance, further solidifying the dominance of this segment.

The sialoendoscopy segment is anticipated to witness the fastest CAGR of 20.4% from 2025 to 2032. This minimally invasive technique allows direct visualization and treatment of the salivary ducts, enabling effective management of recurrent episodes. Sialoendoscopy is increasingly adopted due to reduced complications, shorter recovery times, and high success rates in preventing recurrence. Hospitals and specialized clinics are investing in training and equipment for this procedure, driving its growing adoption globally. Patient preference for less invasive treatment options and the ability to perform therapeutic interventions simultaneously during diagnosis contribute to its rapid market growth.

• By Diagnosis

On the basis of diagnosis, the recurrent parotitis treatment market is segmented into X-ray, computed tomography (CT) scan, magnetic resonance imaging (MRI), sialography, ultrasonography, and others. The ultrasonography segment dominated the largest market revenue share of 42.8% in 2024, owing to its non-invasive nature, accessibility, cost-effectiveness, and ability to provide real-time imaging of salivary glands. Ultrasonography is widely used for initial evaluation, monitoring disease progression, and guiding minimally invasive procedures. Its radiation-free approach and ease of repetition make it highly suitable for pediatric and adult patients alike, enhancing its dominance.

The MRI segment is expected to witness the fastest CAGR of 19.6% from 2025 to 2032. MRI offers high-resolution imaging of soft tissues, precise assessment of glandular inflammation, and detection of structural anomalies. Increasing adoption of MRI in specialized centers, along with rising awareness among clinicians of its diagnostic accuracy, is propelling the segment’s growth. MRI is preferred for complex or recurrent cases where conventional imaging modalities may not provide sufficient detail, further boosting its use in advanced healthcare settings.

• By Symptoms

On the basis of symptoms, the recurrent parotitis treatment market is segmented into fever, inflammation of the parotid gland, redness, recurrence of inflammation and swelling in repeated episodes, pain, and others. The recurrence of inflammation and swelling in repeated episodes segment dominated the market with 44.0% in 2024, as recurrent episodes are a hallmark feature prompting clinical intervention. Globally, this symptom is the most critical driver for clinical consultations, particularly in North America and Europe, where access to advanced diagnostic tools and specialist care facilitates early detection and management. The increasing prevalence of juvenile recurrent parotitis and adult chronic cases across Asia-Pacific and Latin America further underscores the need for repeat monitoring and intervention. The recurrence of episodes not only impacts patient quality of life but also drives demand for therapeutic solutions such as sialendoscopy, immunomodulatory treatments, and anti-inflammatory drugs. Healthcare providers are investing in patient education programs to improve adherence to long-term treatment plans and minimize the frequency and severity of episodes, which supports the segment’s continued market dominance.

The pain segment is expected to witness the fastest CAGR of 18.9% from 2025 to 2032, as pain management is critical for patient comfort and compliance. Across global markets, there is growing awareness of how recurrent parotitis-associated pain affects daily life, work productivity, and psychological well-being. This has led to increased adoption of analgesics, corticosteroids, non-steroidal anti-inflammatory drugs, and supportive therapies. In emerging regions such as Asia-Pacific and Latin America, governments and healthcare providers are emphasizing pain management protocols, driving the integration of pain-focused treatment strategies in both hospitals and outpatient clinics. Pharmaceutical and biotech companies are increasingly focusing on developing symptom-targeted therapies that provide faster relief and improve long-term patient outcomes, further fueling segment growth.

• By Dosage

On the basis of dosage, the recurrent parotitis treatment market is segmented into injection, tablets, and others. The tablets segment dominated the largest market revenue share of 46.1% in 2024, owing to ease of use, patient compliance, and suitability for long-term prophylactic therapy. Globally, tablets remain the preferred dosage form due to their convenience, portability, and cost-effectiveness, especially for pediatric and adult populations managing chronic or recurrent parotitis. Tablets are widely available in developed markets such as North America and Europe, where insurance coverage and structured outpatient care encourage consistent adherence. In emerging markets, tablets are accessible and affordable, supporting broader patient reach. Pharmaceutical companies are increasingly formulating pediatric-friendly, flavored, or dissolvable tablets to enhance acceptance among children and improve long-term therapy compliance. The segment benefits from both prophylactic use and symptom management during recurrent episodes, making it a globally dominant dosage form.

The injection segment is expected to witness the fastest CAGR of 20.1% from 2025 to 2032, as injectable therapies are increasingly used for acute flare-ups or when oral medications are insufficient. Globally, injections are preferred in hospitals and specialized clinics where immediate therapeutic intervention is required, including corticosteroids or biologics administered intravenously or intramuscularly. The segment is particularly growing in North America, Europe, and parts of Asia-Pacific due to increased adoption of hospital-based treatment protocols and innovations in injectable formulations that offer targeted and rapid relief. Rising investments in R&D for novel parenteral drugs, coupled with increased training of healthcare professionals, are accelerating the availability and adoption of injections in managing severe and acute recurrent parotitis cases.

• By Route of Administration

On the basis of route of administration, the recurrent parotitis treatment market is segmented into oral, parenteral, and others. The oral segment dominated the market with a revenue share of 45.7% in 2024, due to its convenience, non-invasiveness, and suitability for both outpatient and home-based management. Globally, oral administration is preferred in both pediatric and elderly populations as it ensures high patient adherence and reduces hospital visits. In North America and Europe, structured treatment regimens and telemedicine support enhance the effectiveness of oral therapy. Emerging regions, including parts of Asia and Latin America, are witnessing a rise in awareness and accessibility of oral medications, contributing to the segment’s dominance. Oral administration is also preferred for long-term prophylaxis and managing recurrent episodes, making it a cost-effective and scalable option across healthcare systems worldwide.

The parenteral segment is expected to witness the fastest CAGR of 19.8% from 2025 to 2032, as parenteral administration is preferred for acute or severe cases requiring rapid therapeutic effect, including intravenous or intramuscular interventions. Globally, hospitals and specialized clinics are increasingly using parenteral formulations to manage high-risk patients or those unresponsive to oral medications. Technological advancements in parenteral drug stability, targeted delivery, and patient safety have made this route more effective and acceptable. Growth in this segment is further fueled by rising hospitalizations for severe parotitis cases in North America, Europe, and emerging markets, along with training programs for healthcare professionals that improve adoption of advanced therapeutic protocols.

• By End-Users

On the basis of end-users, the recurrent parotitis treatment market is segmented into clinics, hospitals, and others. The hospitals segment dominated the largest market revenue share of 48.5% in 2024, attributed to their comprehensive diagnostic and treatment facilities, including access to advanced imaging, minimally invasive procedures, and specialized medical staff. Globally, hospitals are the primary care sites for severe and recurrent parotitis cases due to their ability to provide integrated care, including sialendoscopy, imaging-guided interventions, and multidisciplinary management. Developed regions such as North America and Europe demonstrate high hospital utilization due to better insurance coverage, advanced technology, and structured care pathways. Emerging regions are also increasingly investing in hospital infrastructure to manage chronic parotitis cases, contributing to segment growth.

The clinics segment is expected to witness the fastest CAGR of 21.0% from 2025 to 2032. Outpatient clinics worldwide, particularly ENT and pediatric specialty centers, are increasingly adopting advanced treatments like sialendoscopy and minimally invasive procedures. Clinics provide accessible care for patients with mild to moderate conditions, reducing dependency on hospital resources. Rapid expansion of specialized clinics in Asia-Pacific, the Middle East, and Latin America, combined with patient awareness programs, telemedicine support, and outpatient treatment accessibility, is fueling segment growth. Clinics are becoming increasingly preferred for repeat visits and routine monitoring of recurrent parotitis patients, supporting global adoption.

• By Distribution Channel

On the basis of distribution channel, the recurrent parotitis treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the largest market revenue share of 47.2% in 2024, owing to its direct association with inpatient and outpatient treatment services. Globally, patients receive prescribed medications and therapies conveniently within hospital settings, including oral, injectable, and combination therapies. Hospitals provide integrated dispensing services aligned with diagnostics and treatment plans, ensuring adherence and minimizing errors. North America and Europe show particularly high hospital pharmacy utilization due to well-established healthcare infrastructure, while emerging regions are expanding hospital pharmacy networks to support chronic and recurrent disease management.

The online pharmacy segment is expected to witness the fastest CAGR of 22.5% from 2025 to 2032, driven by increasing internet penetration, convenience of home delivery, and growing patient preference for digital healthcare solutions. Globally, online pharmacies are expanding rapidly in urban and semi-urban areas across North America, Europe, and Asia-Pacific. Online platforms provide access to both prescription and over-the-counter therapies, often integrated with telemedicine consultations for better patient monitoring. The convenience of doorstep delivery, discreet purchase options, subscription services for recurring medications, and broader accessibility are key factors driving the rapid growth of this segment in both developed and emerging markets.

Recurrent Parotitis Treatment Market Regional Analysis

• North America dominated the recurrent parotitis treatment market with the largest revenue share of 40% in 2024, driven by advanced healthcare infrastructure, growing awareness of salivary gland disorders, and the presence of leading healthcare providers and specialized treatment centers
• The widespread availability of specialized otolaryngology clinics, advanced diagnostic facilities, and adoption of minimally invasive and innovative treatment options, such as sialoendoscopy and targeted therapies
• Increasing government support for healthcare modernization, coupled with rising patient awareness about early diagnosis, is further fueling the demand for recurrent parotitis treatments. In addition, the availability of experienced healthcare professionals and robust reimbursement frameworks enhances patient access to effective treatment options

U.S. Recurrent Parotitis Treatment Market Insight

The U.S. recurrent parotitis treatment market captured the largest revenue share in North America in 2024. This growth is fueled by the widespread availability of specialized otolaryngology clinics, advanced diagnostic facilities, and the adoption of minimally invasive and innovative treatment options. Increasing awareness of salivary gland disorders, combined with high healthcare expenditure and the presence of leading healthcare providers, is driving demand for effective treatments such as sialoendoscopy, parotidectomy, and targeted therapeutics. In addition, the U.S. market benefits from ongoing research, adoption of advanced imaging technologies, and clinical trials, which further strengthen its dominance in the regional and global market.

Europe Recurrent Parotitis Treatment Market Insight

The Europe recurrent parotitis treatment market is projected to expand at a steady CAGR during the forecast period, primarily driven by increasing healthcare investments, technological advancements in diagnostic imaging, and growing awareness of salivary gland disorders. Countries such as Germany, France, and the U.K. are witnessing increased adoption of minimally invasive treatment techniques and advanced therapeutic interventions. Rising patient preference for early diagnosis, coupled with government initiatives promoting healthcare access and innovation, is supporting market growth. Furthermore, well-established hospital networks and research facilities in Europe facilitate the introduction of new treatment options for recurrent parotitis, increasing patient outcomes and treatment efficiency.

U.K. Recurrent Parotitis Treatment Market Insight

The U.K. recurrent parotitis treatment market is expected to grow at a noteworthy CAGR during the forecast period, driven by rising prevalence of salivary gland disorders and increasing demand for minimally invasive treatments. The availability of specialized ENT clinics, coupled with advancements in imaging techniques such as MRI and ultrasonography, enables early diagnosis and effective management of recurrent parotitis. Patient awareness campaigns and healthcare policies that emphasize early intervention and improved treatment outcomes further propel the market. The presence of innovative treatment centers and access to advanced therapeutics is also expected to contribute to sustained market growth in the U.K.

Germany Recurrent Parotitis Treatment Market Insight

The Germany recurrent parotitis treatment market is expected to expand at a considerable CAGR, fueled by growing healthcare infrastructure, technological advancements, and emphasis on minimally invasive treatment options. Hospitals and specialized clinics increasingly adopt sialoendoscopy and targeted parotid therapies to manage recurrent inflammation efficiently. Patient awareness regarding early diagnosis and preventive care is rising, contributing to higher treatment adoption. Moreover, Germany’s strong focus on research and development facilitates the introduction of innovative therapeutic solutions, supporting continued market expansion.

Asia-Pacific Recurrent Parotitis Treatment Market Insight

The Asia-Pacific recurrent parotitis treatment market is expected to be the fastest-growing region in recurrent parotitis treatment during the forecast period, driven by increasing healthcare investments, rising prevalence of salivary gland disorders, and expanding number of specialized treatment centers. Countries such as China, India, and Japan are witnessing growing awareness of early diagnosis and minimally invasive therapies. Improved healthcare infrastructure, availability of advanced diagnostic imaging, and government initiatives to enhance clinical services further support market growth. In addition, the adoption of innovative treatment modalities, coupled with rising patient awareness about disease management, is accelerating the market expansion in APAC.

Japan Recurrent Parotitis Treatment Market Insight

The Japan recurrent parotitis treatment market is gaining momentum due to its advanced healthcare system, high patient awareness, and growing adoption of minimally invasive treatments. Increasing prevalence of salivary gland disorders and demand for convenient, effective therapies contribute to market growth. The integration of modern diagnostic technologies such as ultrasonography and sialoendoscopy in specialized clinics facilitates early diagnosis and personalized treatment plans. Furthermore, Japan’s aging population is likely to drive demand for safe and effective recurrent parotitis therapies in both hospital and outpatient settings.

China Recurrent Parotitis Treatment Market Insight

The China recurrent parotitis treatment market accounted for the largest market revenue share in Asia-Pacific in 2024, driven by rapid urbanization, expanding healthcare infrastructure, and increasing awareness of salivary gland disorders. The country is witnessing growth in specialized otolaryngology centers, advanced diagnostic facilities, and adoption of minimally invasive and innovative therapies. Government initiatives to improve healthcare access and investments in clinical infrastructure are supporting increased diagnosis and treatment rates. Rising patient awareness regarding early intervention, combined with the availability of affordable treatment options, is further propelling the recurrent parotitis treatment market in China.

Recurrent Parotitis Treatment Market Share

The recurrent parotitis treatment industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Sanofi (France)
• Abbott (U.S.)
• Bayer AG (Germany)
• Bristol-Myers Squibb Company (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Johnson & Johnson and its affiliates (U.S.)
• Merck & Co., Inc. (U.S.)
• Melinta Therapeutics LLC (U.S.)
• Basilea Pharmaceutica Ltd. (Switzerland)
• Tetraphase Pharmaceuticals (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• SHIONOGI & Co., Ltd. (Japan)
• AbbVie Inc. (U.S.)
• Cumberland Pharmaceuticals Inc. (U.S.)
• Lilly USA, LLC (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Takeda Pharmaceutical Company Limited (Japan)

Latest Developments in Global Recurrent Parotitis Treatment Market

• In August 2025, a study published in ResearchGate highlighted the promising outcomes of minimally invasive techniques, particularly sialendoscopy, in managing juvenile recurrent parotitis (JRP). The study emphasized the need for larger randomized trials to establish optimal management strategies and understand the natural history of JRP
• In July 2024, a retrospective study published in Acta Otorrinolaringologica evaluated the utility of sialendoscopy in the management of juvenile recurrent parotitis. The study concluded that sialendoscopy is a valuable tool in the treatment of JRP, offering a minimally invasive option with promising outcomes
• In August 2024, a study published in Biomed Central discussed the treatment of juvenile idiopathic recurrent parotitis with short-term antibiotics. The study presented a consecutive case series of patients with more than one decade of follow-up and their dramatic response to short-course treatment with prednisolone
• In August 2024, a study published in ResearchGate evaluated the therapeutic effect of conservative treatment in children with juvenile recurrent parotitis. The study aimed to assess the effectiveness of conservative approaches in managing the condition
• In August 2024, a study published in Medscape provided an overview of recurrent parotitis of childhood, noting repetitious episodes of unilateral or bilateral mumps-like episodes in young children as indicative of the condition

SKU-67515